Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study

Table 2

Tumor and patient characteristics stratified by ER and PR statue.

Characteristics	Total; N = 278 (%)	ER > 10% & PR>20%; N = 201 (%)	ER > 10%&1% ≤ PR ≤ 20% N = 60 (%)	1% ≤ ER < 10%&1% ≤ PR ≤ 20%; N = 17 (%)	value
Age (y)					0.011
<50	130 (46.8%)	104 (51.7%)	18 (30.0%)	8 (47.1%)
≥50	148 (53.2%)	97 (48.3%)	42 (70.0%)	9 (52.9%)
Menstrual status					0.001
Pre/Peri-	133 (47.8%)	109 (54.2%)	16 (26.7%)	8 (47.1%)
Post-	145 (52.2%)	92 (45.8%)	44 (73.3%)	9 (52.9%)
Histology type					0.254
NI&IST	37 (13.3%)	23 (11.4%)	12 (20.0%)	2 (11.8%)
INST	241 (86.7%)	178 (88.6%)	48 (80.0%)	15 (88.2%)
Ki-67					0.308
<14%	170 (61.2%)	126 (62.7%)	32 (53.3%)	12 (70.6%)
≥14%	108 (38.8%)	75 (37.3%)	28 (46.7%)	5 (29.4%)
Tumor size (cm)					0.024
T1	147 (52.2%)	108 (53.7%)	28 (46.7%)	9 (52.9%)
T2	123 (44.2%)	88 (43.8%)	27 (45.0%)	8 (47.1%)
T3	8 (2.9%)	5 (2.5%)	3 (5.0)	0 (0.0%)
T4	2 (0.7%)	0 (0.0%)	2 (3.3%)	0 (0.0%)
ALN status					0.190
0	186 (66.9%)	137 (68.2%)	38 (63.3%)	11 (64.7%)
1–3	64 (23.0%)	51 (25.4%)	11 (18.3%)	2 (11.8%)
≥4	28 (10.1%)	13 (6.5%)	11 (18.3%)	4 (23.5%)
Stage					0.008
0–I	112 (40.3%)	83 (41.3%)	22 (36.7%)	7 (41.2%)
II	133 (47.8%)	103 (51.2%)	24 (40.0%)	6 (35.3%)
III	33 (11.9%)	15 (7.5%)	14 (23.3%)	4 (23.5%)
Surgical procedure					0.882
BCS	27 (9.7%)	18 (9.0%)	7 (11.7%)	2 (11.8%)
SM	16 (5.8%)	11 (5.5%)	5 (8.3%)	0 (0.0%)
MRM	211 (75.9%)	153 (76.1%)	44 (73.3%)	14 (82.4%)
ERM	24 (8.6%)	19 (9.5)%	4 (6.7%)	1 (5.9%)